Pharmaceutical giant Pfizer Inc. (NYSE: PFE) stock is trading back down near its pandemic lows. Every time it attempts to climb over the $30 mark, something causes shares to slide right back down. Despite the disheartening price action, this medical sector giant is still one of the world’s largest research-based biopharmaceutical companies behind Eli Lilly & Co. (NYSE: LLY).
Pfizer is trading at a bargain valuation at just 9.1x forward earnings with a tasty 6.46% annual dividend yield. Here are four more reasons to consider this stock for your portfolio.
